Senhwa Biosciences, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
9
Ending by 2030
Jul 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 23, 2026The maintenance fee for Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators (US 9,062,043) comes due Dec 23, 2026. Unpaid by Jun 23, 2027, it lapses early.
- 1 fee due Jan 11, 2027The maintenance fee for Antiviral compounds and method for treating RNA viral infection, particularly COVID-19 (US 11,696,911) comes due Jan 11, 2027. Unpaid by Jul 12, 2027, it lapses early.
- 1 fee due Oct 5, 2027The maintenance fee for Pyrazolopyrimidines and related heterocycles as CK2 inhibitors (US 9,303,033) comes due Oct 5, 2027. Unpaid by Apr 5, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 23, 2026
- Oct 20 US 7,652,134 Methods for converting quinolone esters into quinolone amides · term ended
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,816,406 | Quinolone analogs In force · USPTO record | In force | USPTO record | |
| US 7,816,524 | Methods of preparing quinolone analogs In force · USPTO record | In force | USPTO record | |
| US 9,062,043 | Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators In force · USPTO record | In force | USPTO record | |
| US 7,910,600 | Therapeutic kinase modulators In force · USPTO record | In force | USPTO record | |
| US 8,853,234 | Quinolone analogs and methods related thereto In force · USPTO record | In force | USPTO record | |
| US 7,928,100 | Quinolone analogs and methods related thereto In force · USPTO record | In force | USPTO record | |
| US 7,956,064 | Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators In force · USPTO record | In force | USPTO record | |
| US 8,367,681 | Pyrazolopyrimidines and related heterocycles as kinase inhibitors In force · USPTO record | In force | USPTO record | |
| US 9,303,033 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors In force · USPTO record | In force | USPTO record | |
| US 8,575,177 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 18: 1 lapsed for an unpaid fee · 2 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 5 no status recorded